We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $581M Turnover 56.9%
1-Year Est. Return 373.68%
This Fund
S&P 500
This Quarter Est. Return
+35.11%
1 Year Est. Return
+373.68%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$581M
AUM Growth
+$58.2M
Cap. Flow
-$54.7M
Cap. Flow %
-9.43%
Top 10 Hldgs %
40.99%
Holding
116
New
34
Increased
19
Reduced
30
Closed
32
Avg Time Held Equity + Options
0.4 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
0.5 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.5 years

Top Buys

Rank Stock Value
1
TNGX icon
Tango Therapeutics
TNGX
+$25.3M
2
ERAS icon
Erasca
ERAS
+$19M
3
TYRA icon
Tyra Biosciences
TYRA
+$14.5M
4
TRAX icon
First Tracks Biotherapeutics
TRAX
+$11.6M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$10.9M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$38.5M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$28.4M
3
RVMD icon
Revolution Medicines
RVMD
+$17.8M
4
MBX icon
MBX Biosciences
MBX
+$14.9M
5
IMVT icon
Immunovant
IMVT
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.23%
2 Miscellaneous 0.45%
3 Financials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
NRIX icon
101
Nurix Therapeutics
NRIX
$2.72B
– –
-315,226
Closed -$4.89M –
OLMA icon
102
CALL
Olema Pharmaceuticals
OLMA
$622M
– –
-25,000
Closed -$3.75K –
PCVX icon
103
Vaxcyte
PCVX
$10B
– –
-59,061
Closed -$3.43M –
QQQ icon
104
CALL
Invesco QQQ Trust
QQQ
$485B
– –
-40,000
Closed -$74.2K –
SNDX icon
105
CALL
Syndax Pharmaceuticals
SNDX
$1.17B
– –
-150,000
Closed -$90K –
SNDX icon
106
Syndax Pharmaceuticals
SNDX
$1.17B
– –
-1,215,743
Closed -$28.4M –
FTH icon
107
Faeth Therapeutics
FTH
$502M
– –
-132,873
Closed -$4.19M –
SPY icon
108
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$817B
– –
-50,000
Closed -$85.5K –
SRRK icon
109
CALL
Scholar Rock
SRRK
$4.9B
– –
-100,000
Closed -$588K –
STRO icon
110
Sutro Biopharma
STRO
$187M
– –
-23,295
Closed -$580K –
TERN icon
111
CALL
DELISTED
Terns Pharmaceuticals
TERN
– –
-100,000
Closed -$7.5K –
TWST icon
112
Twist Bioscience
TWST
$9.27B
– –
-43,110
Closed -$2.05M –
TYRA icon
113
CALL
Tyra Biosciences
TYRA
$1.33B
– –
-100,000
Closed -$290K –
XFOR icon
114
X4 Pharmaceuticals
XFOR
$273M
– –
-850,742
Closed -$3.51M –
MBX icon
115
MBX Biosciences
MBX
$2.53B
– –
-499,469
Closed -$14.9M –
EVMN icon
116
Evommune Inc
EVMN
$191M
– –
-193,777
Closed -$4.39M –
1 2 3 4
5

Similar funds

PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
MIP
Marietta Investment Partners Milwaukee, Wisconsin $582M AUM 54.15% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM
LCM
Liberty Capital Management Birmingham, Michigan $582M AUM

Stempoint Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Stempoint Capital held 116 positions worth $581M, up 11% from $522M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Stempoint Capital withdrew a net $54.7M in Q2 2026, closing 32 positions and reducing 30 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $28.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Stempoint Capital opened a new position in First Tracks Biotherapeutics worth $12.5M.

  • Stempoint Capital's largest Q2 2026 buy was First Tracks Biotherapeutics: 622,723 shares worth $12.5M.
  • Stempoint Capital added most to Tango Therapeutics in Q2 2026, an estimated $25.3M increase.
  • Stempoint Capital's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $38.5M.
  • Stempoint Capital fully exited Syndax Pharmaceuticals in Q2 2026, selling an estimated $28.4M.
  • Stempoint Capital's ten largest holdings make up 41% of its $581M portfolio in Q2 2026.
  • Stempoint Capital opened 34 new positions and closed 32 in Q2 2026.
  • Stempoint Capital's portfolio value rose 11% quarter-over-quarter to $581M.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.